Entrada Therapeutics, Inc.TRDA
What Entrada Therapeutics, Inc. does.
We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by e stablishing a new class of medicines that engage intracellular targets that have long been considered inaccessible . Through proprietary, versatile and modular approaches, we are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. In 2026, we expect to progress our ENTR-601-44 and ENTR-601-45 clinical trials, an EU filing for the ENTR-601-50 clinical trial, and regulatory submissions for ENTR-601-51. In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated (“Vertex”) continues to progress, with dosing completion anticipated in mid-2026. We anticipate reporting on the results of two cohorts of patient data from our ENTR-601-44 program, and one from our ENTR-601-45 program during 2026.
Entrada continues to advance multiple clinical programs in people living with Duchenne muscular dystrophy (“DMD”) in the United Kingdom (“UK”), European Union (“EU”) and United States (“U.S.”). In 2026, we expect to have four clinical-stage programs in its DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51). When combined, we estimate that there are over 11,500 patients in the U.S. and Europe that carry mutations amenable to Entrada's current exon skipping programs. Complementing the ongoing clinical progress of the DMD franchise is the myotonic dystrophy type 1 (“DM1”) partnership with Vertex (“VX-670”). Each of these programs utilize the same endosomal escape vehicle, and as such, we anticipate initial data readouts from any one of the candidate clinical trials to provide critical insights for the rest.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $129.0M | $210.8M | $25.4M |
| Net income | -$26.5M | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M |
| Free cash flow | -$27.9M | -$55.4M | -$96.7M | $134.2M | -$44.7M | -$129.6M |
More on TRDA.
- Entrada Therapeutics, Inc. summary
- Entrada Therapeutics, Inc. financial statements
- Entrada Therapeutics, Inc. key metrics
- Entrada Therapeutics, Inc. health scores and style box
- Entrada Therapeutics, Inc. earnings
- Entrada Therapeutics, Inc. dividends
- Entrada Therapeutics, Inc. valuation
- Entrada Therapeutics, Inc. ownership and insiders
- Entrada Therapeutics, Inc. peers
Figures from Entrada Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.